Idera Reports Positive Trial Results By: MarketMinute.com Stock News March 28, 2014 at 14:48 PM EDT Idera Pharmaceuticals Inc. (Nasdaq: IDRA) reported positive results from a Phase 2 trial of its psoriasis treatment IMO-8400 sending the stock price up 64 cents to $4.52. Related Stocks: Idera Pharmaceuticals